<DOC>
	<DOCNO>NCT02214979</DOCNO>
	<brief_summary>Study demonstrate bioequivalence ( BE ) 40 mg telmisartan/ 2.5 mg ramipril fixed-dose combination ( FDC ) versus monocomponents give concomitantly</brief_summary>
	<brief_title>Bioequivalence Telmisartan / Ramipril Fixed Dose Combination Compared With Monocomponents Given Concomitantly Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Healthy male female accord follow criterion base upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age ≥18 Age ≤55 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial ( especially unspecific induce agent like St.John´s wort ( Hypericum perforatum ) inhibitor like cimetidine ) prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke 24 hour prior dose 24 hour dose Alcohol abuse ( 60 g/day ) inability stop alcoholic beverage 24 hour prior dose last sampling time point , 96 hour dose . Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hyperkalemia , hypokalemia , family history Long QT Syndrome ) Any history relevant low blood pressure Supine blood pressure screen systolic &lt; 110 mm Hg diastolic &lt; 60 mm Hg History urticaria History angioneurotic edema Hereditary fructose intolerance For female subject : Pregnancy plan become pregnant study within 2 month study completion Positive pregnancy test Are willing unable use reliable method contraception ( implant , injectables combine oral contraceptive , sterilisation , intrauterine device , double barrier method , sexual abstinence ) least 1 month prior participation trial , 1 month completion/termination trial Chronic use oral contraception hormone replacement contain ethinyl estradiol method contraception Currently lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>